8-Cl-adenosine-induced inhibition of colorectal cancer growth in vitro and in vivo

被引:20
作者
Carlson, CC
Chinery, R
Burnham, LL
Dransfield, DT
机构
[1] Med Coll Georgia, Inst Mol Med & Genet, Cell Biol Program, Augusta, GA 30912 USA
[2] Med Coll Georgia, Dept Gen Surg, Augusta, GA 30912 USA
[3] Augusta VA Med Ctr, Augusta, GA USA
[4] Mayo Clin & Mayo Fdn, Res Unit G1, Rochester, MN 55905 USA
来源
NEOPLASIA | 2000年 / 2卷 / 05期
关键词
8-Cl-adenosine; colorectal cancer; cell cycle; endoreduplication; xenograft;
D O I
10.1038/sj.neo.7900106
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cAMP analogue 8-Cl-cAMP induces apoptosis and inhibits proliferation of a wide variety of malignancies in vitro and in vivo with relatively little toxicity, The antitumor effects of this compound are thought to involve its ability to modulate type I protein kinase A (PKAI), However, a nontoxic metabolite of 8-Cl-cAMP, 8-Cl-adenosine, with no known activity against PKAI, exerts growth inhibitory effects in breast, ovary, pancreas, and colorectal cancer cells in vitro and accumulates in xenografted tumors after 8-Cl-cAMP treatment in vivo. To characterize further the antitumor effects of 8-Cl-adenosine in colorectal cancer, we examined its effects on cell growth in vitro (cell number, H-3-thymidine incorporation, and soft agar colony formation) using the isogenically matched colorectal cancer cell lines HCT116, HCT116-E6 (p53-depleted), and 80S14 (p21(WAF1/Cip1)-null). 8-Cl- adenosine inhibited cell growth by 89%, 74%, and 79%, respectively in HCT116, HCT116-E6, and 80S14 cells after a 72-hour exposure, Growth inhibition coincided with DNA endoreduplication and subsequent apoptosis. Furthermore, nontoxic doses of 8-Cl-adenosine administered i.p. twice weekly for 4 weeks to athymic mice suppressed growth of HCT116-derived xenografts by 50%. These results show that 8-Cl-adenosine exerts antitumor activity against colorectal cancer independent of p53 and p21(WAF1/Cip1).
引用
收藏
页码:441 / 448
页数:8
相关论文
共 17 条
[1]  
Benson AB, 1998, SEMIN ONCOL, V25, P2
[2]  
BOLAND R, 2000, GASTRO, V118, pS115
[3]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[4]   Mismatch repair proficiency and in vitro response to 5-fluorouracil [J].
Carethers, JM ;
Chauhan, DP ;
Fink, D ;
Nebel, S ;
Bresalier, RS ;
Howell, SB ;
Boland, CR .
GASTROENTEROLOGY, 1999, 117 (01) :123-131
[5]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[6]   Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207) [J].
Kooby, DA ;
Carew, JF ;
Halterman, MW ;
Mack, JE ;
Bertino, JR ;
Blumgart, LH ;
Federoff, HJ ;
Fong, YM .
FASEB JOURNAL, 1999, 13 (11) :1325-1334
[7]   P53-DEPENDENT APOPTOSIS MODULATES THE CYTOTOXICITY OF ANTICANCER AGENTS [J].
LOWE, SW ;
RULEY, HE ;
JACKS, T ;
HOUSMAN, DE .
CELL, 1993, 74 (06) :957-967
[8]   8-chloroadenosine 3′,5′-monophosphate (8-Cl-cAMP) selectively eliminates protein kinase A type I to induce growth inhibition in c-ras-transformed fibroblasts [J].
Noguchi, K ;
Murata, T ;
Cho-Chung, YS .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (08) :1260-1267
[9]  
PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896
[10]  
Pritchard DM, 1998, CANCER RES, V58, P5453